CUE BIOPHARMA INC. - COMMON STOCK

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

12 May 2025 13:05:01 By Nasdaq GlobeNewswire

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

08 May 2025 05:00:01 By Nasdaq GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

05 May 2025 07:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

14 Apr 2025 19:23:10 By Nasdaq GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

14 Apr 2025 14:05:00 By Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

14 Apr 2025 14:02:00 By Nasdaq GlobeNewswire

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

14 Apr 2025 14:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

31 Mar 2025 13:20:00 By Nasdaq GlobeNewswire

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

29 Nov 2024 13:30:00 By Nasdaq GlobeNewswire

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

25 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 Nov 2024 13:05:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces Strategic Organizational Transition

14 Nov 2024 05:00:09 By Nasdaq GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

12 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

08 Nov 2024 10:30:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

04 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

26 Sep 2024 20:26:30 By Nasdaq GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

26 Sep 2024 20:10:15 By Nasdaq GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

26 Sep 2024 13:27:02 By Nasdaq GlobeNewswire

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

09 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference

03 Sep 2024 05:00:00 By Nasdaq GlobeNewswire